Joinn profit surge and CRO sector rally drive gains
H1 profit forecast surge on biological asset gains Joinn forecast first-half 2026 net profit of 600–900 million yuan, up 884.9%–1,377.4% year-on-year. The jump is mostly from higher market prices and natural growth of biological assets (lab monkeys), not from lab operations, which grew only slightly. This boosts reported earnings and investor sentiment.
This is the primary new company-specific catalyst that directly explains the profit surge and initial stock reaction.
Rising lab monkey prices lift CRO profits The price of cynomolgus monkeys, a key raw material for CROs, climbed to 178,000 yuan. This directly boosts the value of Joinn's biological assets and its profit forecast, as seen across the sector. Higher animal prices support earnings but also raise costs for drug testing services.
It explains the underlying driver of Joinn's profit surge and links it to a sector-wide trend.
CRO sector rally on strong peer earnings and order recovery On August 7, the A-share CRO sector jumped over 7%, with 15 stocks up more than 10%. Strong results from WuXi AppTec and BioMap, plus rising orders from recovering global pharma R&D demand, lifted the whole group including Joinn. This sector momentum supports Joinn's share price.
It shows the broader sector force currently pushing Joinn's stock higher, beyond its own earnings.
Pharmaceutical sector selloff pressures CRO stocks On July 17, the pharmaceutical sector tumbled, with CRO concept stocks like Joinn falling and peers hitting daily limit down. This shows that despite strong earnings, the sector remains sensitive to broad market risk-off moves, which can drag Joinn's price down in the short term.
It provides a real counterweight: sector volatility can still pressure Joinn even amid positive earnings news.